Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype

Journal of the Neurological Sciences

Volumn 207, Issue 1-2, 2003, Pages 19-23

  Nakaso, Kazuhiro ^a,b   Yasui, Kenichi ^a   Kowa, Hisanori ^a   Kusumi, Masayoshi ^a   Ueda, Keigo ^b   Yoshimoto, Yuko ^b   Takeshima, Takao ^a   Sasaki, Kiyohiro ^b   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Hamada Medical Center   (Japan)

Author keywords

Atheroscrelosis; Carotid artery; Folate; Homocysteinemia; Methylenetetrahidrofolate reductase (MTHFR); Ultrasonography

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; LEVODOPA;

AGED; AMINO ACID BLOOD LEVEL; ARTERY INTIMA; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; TUNICA MEDIA;

AGED; ANALYSIS OF VARIANCE; CAROTID ARTERIES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTROPHY; LEVODOPA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC; TUNICA INTIMA;

EID: 12244291003     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00353-2     Document Type: Conference Paper

References (19)

1. Yasui K., Kowa H., Nakaso K., Takeshima T., Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 55:2000;437-440.
2. Kuhn W., Roebroek R., Blom H., van Oppenraaij D., Przuntek H., Kretschmer A.et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol. 40:1998;225-227.
3. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch. Neurol. 57:2000;1422-1427.
4. Kowa H., Yasui K., Urakami K., Takeshima T., Nakashima K. MTHFR polymorphism in patients with Parkinson's disease in Japanese population. Parkinsonism Relat. Disord. 5:1999;S4. [Suppl., Abstract].
5. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocystein as a risk factor for vascular disease. JAMA. 274:1995;1049-1057.
6. Hankey G.J., Eikelboom J.W. Homocysteine and vascular disease. Lancet. 354:1999;407-413.
7. Megnien J.L., Gariepy J., Saudubray J.M., Nuoffer J.M., Denarie N., Levenson J.et al. Evidence of carotid artery wall hypertrophy in homozygous homocystinuria. Circulation. 98:1998;2276-2281.
8. McQuillan B.M., Beilby J.P., Nidorf M., Thompson P.L., Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation. 99(18):1999 (May 11);2383-2388.
9. Blandini F., Fancellu R., Martignoni E., Mangiagalli A., Pacchetti C., Samuele A.et al. Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clin. Chem. 47:2001;1102-1104.
10. Salonen J.T., Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 87:1993;1156-1165.
11. Howard G., Sharrett R., Heiss G., Evans G.W., Chambless L.E., Riley W.A.et al. Carotid artery intimal-medial thickness distribution in general population as evaluated by B-mode ultrasound. ARIC investigaters. Stroke. 24:1993;1297-1304.
12. Hyland K., Bottiglieri T. Measurement of total plasma and cerebrospinal fluid homocysteine by fluorescence following high-perfomance liquid chromatography and precolumn derivatization with o-phthaldialdehyde. J. Chromatogr. 579:1992;55-62.
13. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G.et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
14. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56:1969;111-128.
15. Struck L.K., Rodnitzky R.L., Dobson J.K. Stroke and its modification in Parkinson's disease. Stroke. 21:1990;1395-1399.
16. Iwasaki S., Narabayashi Y., Hamaguchi K., Iwasaki A., Takakusagi M. Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage. J. Neurol. 237:1990;77-79.
17. Levine R.L., Jones J.C., Bee N. Stroke and Parkinson's disease. Stroke. 23:1992;839-842.
18. Muller T., Werne B., Fowler B., Kuhn W. Nigral endothelial dysfunction homocysteine, and Parkinson's disease. Lancet. 354:1999;126-127.
19. Kang S.S., Wong P.W., Norsis M. Homocysteinemia due to folate deficiency. Metabolism. 36:1987;458-462.